Synergistic compositions containing R-2-(substituted sulfonyl)-hexahydro-pyrrolo[1,2-a]pyrazin-6(2H)-one and S-2-(substituted sulfonyl)-hexahydro-pyrrolo[1,2-a]pyrazin-6(2H)-one in non-racemic ratios

JP2022510362A5Inactive Publication Date: 2024-11-26メティスファーマシューティカルズアクチェンゲゼルシャフト
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
JP2021531431
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2018-12-04
Filing Date
2019-12-04
Publication Date
2024-11-26
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

Current treatments for depression, treatment-resistant depression, and other psychiatric disorders such as bipolar disorder, PTSD, obsessive-compulsive disorder, schizophrenia, and anxiety, as well as conditions like peripheral neuropathic pain and spinal muscular atrophy, often have narrow therapeutic indices, undesirable side effects, and require weeks for efficacy, and there is a need for safer, more effective therapeutic agents.

Method used

Development of non-racemic compositions of (R)- and (S)-2-(substituted sulfonyl)-hexahydro-pyrrolo[1,2-a]pyrazin-6(2H)-ones with specific enantiomeric excess, which exhibit synergistic effects in inhibiting glutamate release and treating these conditions.

Benefits of technology

The compositions demonstrate enhanced potency in reducing neuropathic pain, improving cognitive function, and treating psychiatric disorders with fewer side effects and faster onset than racemic or individual enantiomer treatments.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2020115096000001
    Figure 2020115096000001
  • Figure 2020115096000002
    Figure 2020115096000002
Patent Text Reader

Abstract

The present invention relates to a composition of a ratio of enantiomers of 2-(substituted sulfonyl)-hexahydro-pyrrolo[1,2-a]pyrazin-6(2H)-one derivatives and their pharmaceutically acceptable solvates or co-crystals, to a pharmaceutical composition comprising said composition, its use as a medicament, and to the use of the composition or pharmaceutical composition of the invention in the treatment and / or prevention of a disease or disorder typically and preferably selected from peripheral sensory neuropathy, preferably peripheral neuropathic pain; stroke; depression; or cognitive impairment.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical Field]

[0001] The present invention relates to compositions and kits comprising R-2-(substituted sulfonyl)-hexahydro-pyrrolo[1,2-a]pyrazine-6(2H)-one and S-2-(substituted sulfonyl)-hexahydro-pyrrolo[1,2-a]pyrazine-6(2H)-one and pharmaceutically acceptable solvates or cocrystals thereof in a certain range of ratios, pharmaceutical compositions comprising such compositions, their use as pharmaceuticals, and typically and preferably for depression and treatment-resistant depression, bipolar disorder, post-traumatic stress disorder, obsessive-compulsive disorder, autism spectrum disorder The present invention relates to the use of compositions or pharmaceutical compositions or kits for the treatment and / or prevention of mental disorders or disorders selected from pectrum disorders, schizophrenia, and anxiety; symptoms of peripheral sensory neuropathy, preferably peripheral neuropathic pain and cold allodynia, acute and chronic central hypersensitivity disorders such as fibromyalgia, irritable bowel syndrome, migraine, and cluster headache; and motor neuron disorders such as spinal muscular atrophy, amyotrophic lateral sclerosis, Parkinson's dystonia, and Huntington's dystonia. [Background technology]

[0002] Glutamate is an excitatory neurotransmitter widely present in the brain. Its role as an excitatory messenger was first observed in the 1950s, when intravenous administration of glutamate was recognized as inducing seizures. However, the detection of the entire glutamatergic neurotransmitter system, including its biosynthesis and degradation enzymes, cellular uptake mechanisms, intracellular storage and release systems, and its cell surface ion channels and G protein-coupled receptors, was not achieved until the 1970s, and suitable pharmacological tools were first identified in the 1980s. It wasn't until the 1990s that newly emerging molecular biological tools provided means for the molecular identification and classification of glutamatergic ion channels, receptors, transporters, and other related molecules. Membrane-bound ion channels, which are opened and closed by the excitatory amino acids glutamate and glycine and also respond to the xenobiotic compound N-methyl-D-aspartate (NMDA), regulate the influx of both divalent and monovalent cations into presynaptic and postsynaptic nerve cells (see Foster et al., Nature 1987, 329:395-396; Mayer et al., Trends in Pharmacol. Sci. 1990, 11:254-260). They are molecularly, electrophysiologically, and pharmacologically distinct from glutamate-opening cation-conducting ion channels that respond to the xenobiotic substances kinates or α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA), and are similarly distinct from the family of glutamate-opening G protein-coupled receptors, the so-called metabotropic glutamate receptors.

[0003] The NMDA-preferential glutamate-opening ion channel has a heterotetrameric structural base consisting of two essential GluN1 units and two variable GluN2 receptor subunits, each encoded by the GRIN1 gene and one of four GRIN2 genes. One or both GluN2 subunits can potentially be replaced by GluN3A or GluN3B subunits. The GRIN1 gene product has eight splice variants, while there are four different GRIN2 genes (GRIN2A-D) encoding four different GluN2 subunits. The glycine-binding site is located on the GluN1 subunit, and the glutamate-binding site is located on the GluN2 subunit (Paoletti P et al., Nat Rev Neurosci. 2013; 14(6):383-400). Compounds that modulate NMDA receptor function are used to treat bipolar disorder (Martucci L et al., Schizophrenia Res, 2006; 84(2-3):214-21), major depressive disorder (Li N et al., Biol Psychiatry. 2011; 69(8):754-61), treatment-resistant depression (Preskorn SH et al. J Clin Psychopharmacol. 2008; 28(6):631-7), and other mood disorders (including schizophrenia (Grimwood S et al., Neuroreport. 1999; 10(3):461-5), prenatal and postnatal depression (Weickert CS et al. Molecular Psychiatry (2013) 18, 1185-1192), seasonal affective disorder, etc.); and Alzheimer's disease (Hanson JE et al., Neurobiol Dis. 2015; 74:254-62; Li S et al., J Neurosci. 2011; 31(18):6627-38) and other dementias (Orgogozo JM et al. Stroke 2002, 33: 1834-1839), Parkinson's disease (Duty S, CNS Drugs. 2012; 26(12):1017-32; Steece-Collier K et al., Exp Neurol. 2000; 163(1):239-43; Leaver KR et al. Clin Exp Pharmacol Physiol. 2008; 35(11):1388-94), Huntington's disease (Tang TS et al., Proc Natl Acad Sci USA. 2005; 102(7):2602-7; Li L et al., J Neurophysiol. 2004; 92(5):2738-46), multiple sclerosis (Grasselli G et al., Br J Pharmacol. 2013; 168(2):502-17), and cognitive impairment (Wang D et al. 2014, Expert Opin Ther Targets 2014; 18(10):1121-30), head trauma (Bullock MR et al., Ann NY Acad Sci. 1999; 890:51-8), spinal cord injury, stroke (Yang Y et al., J Neurosurg. 2003; 98(2):397-403), epilepsy (Naspolini AP et al., Epilepsy Res. 2012 Jun; 100(1-2):12-9), motor disorders (e.g., dyskinesia) (Morissette M et al., Mov Disord. 2006; 21(1):9-17), various neurodegenerative diseases (e.g., amyotrophic lateral sclerosis (Fuller PI et al., Neurosci Lett. 2006; 399(1-2):157-61) or neurodegeneration associated with bacterial or chronic infection, glaucoma (Naskar R et al. Semin Ophthalmol. 1999) Sep; 14(3):152-8), pain (e.g., chronic, cancer, postoperative and neuropathic pain (Wu LJ and Zhuo M, Neurotherapeutics. 2009; 6(4):693-702), diabetic neuropathy, migraine (Peeters M et al., J Pharmacol Exp Ther. 2007; 321(2):564-72), cerebral ischemia (Yuan H et al., Neuron. 2015; 85(6):1305-18), encephalitis (Dalmau J. et al., Lancet Neurol. 2008; 7(12):1091-8), autism and autism spectrum disorder (Won H. et al., Nature. 2012; 486(7402):261-5), memory and learning disabilities (Tang, YP et al., Nature. 1999; 401(6748):63-9), obsessive-compulsive disorder (Arnold PD et al., Psychiatry Res. 2009; 172(2):136-9), attention-deficit hyperactivity disorder (ADHD) (Dorval KM et al., Genes Brain Behav. 2007; 6(5):444-52), Post-Traumatic Stress Disorder (PTSD) (Haller J et al. Behav Pharmacol.2011; 22(2):113-21; Leaderbrand K et al. Neurobiol Learn Mem. 2014; 113:35-40), tinnitus (Guitton MJ, and Dudai Y, Neural Plast. 2007; 80904; Hu SS et al. 2016; 273(2): 325-332), sleep disorders (sleep disorders such as narcolepsy or excessive daytime sleepiness, International Publication No. 2009 / 058261), dizziness and nystagmus (Straube A. et al., Curr Opin Neurol. 2005; 18(1):11-4; Starck M et al. J Neurol. 1997 Jan; 244(1):9-16), anxiety, autoimmune disorders such as neuropsychiatric systemic lupus erythematosus (Kowal C et al. Proc. Natl. It may be useful in the treatment of many neurological and psychiatric disorders, including, but not limited to, addiction disorders (e.g., alcohol addiction, drug addiction) (Nagy J, 2004, Curr Drug Targets CNS Neurol Disord. 2004; 3(3):169-79.; Shen H et al., Proc Natl Acad Sci USA. 2011; 108(48):19407-12).

[0004] Recent human clinical studies have identified NMDA-type glutamate-opening ion channels as a very interesting novel target for the treatment of depression (Singh JB et al., Biol Psychiatry 2016; 80(6):424-431; Preskorn SH et al. J Clin Psychopharmacol 2008; 28(6):631-7). These studies, conducted using the known NMDA receptor antagonists ketamine and CP-101606, showed a significant reduction in depression rating scores in patients with treatment-refractory depression. While the efficacy was remarkable, the side effects of using these NDMA receptor antagonists were problematic.

[0005] NMDA-modulated small molecule agonists and antagonists have been developed for potential therapeutic use. However, many of these have very narrow therapeutic indices, as well as undesirable side effects, including hallucinations, ataxia, irrational behavior, and significant toxicity, all of which limit their efficacy and / or safety. Furthermore, more than 50% of patients with depression do not experience a sufficient therapeutic response to known administered drugs. In most cases, more than two weeks of pharmacotherapy are required before meaningful improvement is observed, as is evident in open-label studies on the pharmacological treatment of depression (Rush et al, Am. J. Psychiatry 2006, 163:1905).

[0006] Symptoms of peripheral sensory neuropathy, including peripheral neuropathic pain (Zilliox LA, 2017), one of the most prominent symptoms of peripheral sensory neuropathy, are frequently encountered clinical conditions. The prevalence in the general population was estimated to be between 7% and 10% (van Hecke O et al., 2014). In the United States, painful diabetic peripheral neuropathy alone is estimated to affect approximately 10 million people. Peripheral sensory neuropathy is often resistant to treatment and is associated with low patient satisfaction with these treatments. Several medications have been shown to be effective in treating peripheral sensory neuropathy associated with diabetic neuropathy and postherpetic neuralgia. These medications are often used to treat neuropathic pain associated with other conditions as well. These treatments often exhibit undesirable adverse effects, and discontinuation of treatment can be problematic. It is important to recognize that peripheral sensory neuropathy affects many aspects of daily life and is associated with poor overall health, reduced quality of life, shallow sleep, and increased anxiety and depression. In fact, the quality of life in patients with chronic peripheral sensory neuropathy was assessed as being as low as that of patients with clinical depression, coronary artery disease, subacute myocardial infarction, or poorly controlled diabetes (Smith BH et al., 2007).

[0007] The neuropathic pain medications approved by the U.S. Food and Drug Administration are carbamazepine, duloxetine, pregabalin, gabapentin, topical lidocaine, and topical capsaicin. Tramadol and opioid analgesics are effective for various types of neuropathic pain, but are generally not recommended as first-line treatments due to concerns about long-term safety. However, they are recommended as first-line treatments for acute neuropathic pain, cancer-related neuropathic pain, and recurrent exacerbations of severe neuropathic pain. The use of potent opioids (codeine, morphine, oxycodone, and fentanyl) in the treatment of various neuropathic pain conditions is controversial, and public health concerns are compounded by the increasing number of deaths associated with medical opioids. The significant risks of overdose, dependence, and addiction associated with these drugs may outweigh the potential benefits.

[0008] Therefore, there remains an urgent and important medical need to develop novel therapeutic agents that are effective orally for the prevention and treatment of neuropathic pain, as well as depression and other mental states, are toxicologically benign, and have no potential for hallucinogenic dependence or addiction. 5 th There remains a significant medical need to develop novel, orally administered therapeutic agents for neuropsychiatric disorders, such as those listed in the version of the Diagnostic and Statistical Manual of Mental Disorders (DSM-5), and motor neuron diseases such as amyotrophic lateral sclerosis (ALS). ((RS)-2-[(4-fluorophenyl)sulfonyl]hexahydropyrrolo[1,2-a]pyrazine-6-one is a bicyclic 2-pyrrolidinone derivative with nootropic activity. Racemic 2-[(4-fluorophenyl)sulfonyl]-hexahydropyrrolo[1,2-a]pyrazine-6(2H)-one has potent nootropic activity than the corresponding single R-enantiomer, and the single R-enantiomer has potent nootropic activity than the corresponding S-enantiomer (Martini et al., Med Chem. 2005, 1(5), pages 473-480). The synthesis of ((RS)-2-[(4-fluorophenyl)sulfonyl]hexahydropyrrolo[1,2-a]pyrazine-6-one) and several derivatives is described in International Publication No. 2009 / 103176, and their stereoselective synthesis is described in Martini et al., Med Chem. 2005, 1(5), pages 473-480. Pharmacological properties and structure-activity relationship studies are disclosed in Romanelli et al., CNS Drug Rev. 2006, 12(1), pages 39-52; Scapecchi et al., Bioorg Med Chem. 2004, 12(1), pages 71-85; Galeotti et al., Naunyn Schmiedebergs Arch Pharmacol. 2003, 368(6), pages 538-45; and Martini et al., Med Chem. 2005, 1(5), pages 473-480. In summary of the available reports, (RS)-2-[(4-fluorophenyl)sulfonyl]hexahydropyrrolo[1,2-a]pyrazine-6(2H)-one and its R-enantiomer can be considered broadly effective oral therapeutic agents in rat cognitive models.

[0009] As reported in a prior patent application (International Publication No. 2009 / 103176), racemic 2-phenylsulfonyl-hexahydro-pyrrolo[1,2-a]pyrazine-6(2H)-one also exhibits anti-hyperalgesic and anti-allodynic effects in a variety of animal models in which neuropathic pain is caused by various agonists or surgical complications. In all test animal models, racemic 2-phenylsulfonyl-hexahydro-pyrrolo[1,2-a]pyrazine-6(2H)-one exhibits a better potency and efficacy profile than the standard therapeutic agents gabapentin, pregabalin, or duloxetine. Furthermore, racemic 2-phenylsulfonyl-hexahydro-pyrrolo[1,2-a]pyrazine-6(2H)-one exhibits a better potency and efficacy profile than the corresponding single R-enantiomer, and the single R-enantiomer is superior to the single S-enantiomer. The efficacy of racemic 2-phenylsulfonyl-hexahydropyrrolo[1,2-a]pyrazine-6(2H)-one is evident after a single oral dose. Furthermore, these anti-hyperalgesic and anti-allodynic effects are disease-specific, as they are undetectable in normal animals and respond to oral administration of the drug only on the injured side in rats in an asymmetric surgical model of nerve crush injury.

[0010] Dimiracetam, also known as (RS)-3,6,7,7a-tetrahydro-1H-pyrrolo[1,2-a]imidazole-2,5-dione, is a negative allosteric modulator of the spinal cord NMDA-type glutamate receptor in rat spinal cord synaptosome preparations (Fariello RG, et al. Neuropharmacology. 2014, 81:85-94) and is active after oral administration in rat models of neuropathic pain, depression, and cognitive impairment (Pinza M, et al. J Med Chem 1993, 36(26):4214-20). Surprisingly, the inventors found that a non-racemic mixture of R and S-dimiracetam leads to superior activity compared to the single enantiomer and the racemic mixture. This finding forms the basis of concurrently pending international application PCT / EP2018 / 064125, which is incorporated herein by reference in its entirety.

Summary of the Invention

[0011] Surprisingly and unexpectedly, it has now been found that compositions of the (R)- and (S)-enantiomers of several 2-(substituted sulfonyl)-hexahydro-pyrrolo[1,2-a]pyrazin-6(2H)-ones having an enantiomeric excess (ee) of from 20% to 50% of the (R)-enantiomer exhibit a higher pharmacological potency than the corresponding individual enantiomers or the racemate, and thus provide a synergistic effect that could not be predicted based on the potency of the individual enantiomers or the racemate. Accordingly, these non-racemic compositions potently inhibit the release of 3 [3H]-D-aspartic acid (used as a mimic of glutamic acid) from rat brain or spinal cord synaptosomes induced by NMDA + glycine, more potently than the corresponding individual enantiomers or the corresponding racemate. Further, in neuropathic pain, cognitive ability, depression models, and other models in which rodent glutamate signaling is thought to be involved, these non-racemic compositions are more potent than the corresponding individual enantiomers or the corresponding racemate. Thus, the compositions of the present invention having an enantiomeric excess of (R)-2-(substituted sulfonyl)-hexahydro-pyrrolo[1,2-a]pyrazin-6(2H)-one are far more efficient than the corresponding racemic mixture in reducing peripheral neuropathic pain in the paw-pressure test after administration of sodium monoiodoacetate; or in preventing oxaliplatin-induced peripheral neuropathic pain; or in improving cognitive function in the step-through type passive avoidance assay; or in increasing swimming time in the Porsolt model of depression.

[0012] Thus, the compositions of the present invention of the (R)- and (S)-enantiomers of 2-(substituted sulfonyl)-hexahydro-pyrrolo[1,2-a]pyrazin-6(2H)-one, each having an enantiomeric excess (ee) of the corresponding (R)-enantiomer of 20% or more and 50% or less, are pharmacologically more effective at a given dose compared to the pure enantiomer alone or a racemic mixture of these compounds. The term racemic refers to a 1:1 mixture by mass of the (R)- and (S)-enantiomers, and thus the mixture has an enantiomeric excess (ee) of 0%. Thus, the effects associated with the present invention are surprisingly due to a synergistic effect resulting from a specific range of ratios between the (R)-2-(substituted sulfonyl)-hexahydro-pyrrolo[1,2-a]pyrazin-6(2H)-one and the (S)-2-(substituted sulfonyl)-hexahydro-pyrrolo[1,2-a]pyrazin-6(2H)-one, each represented by formula (I) and (II).

[0013] The compositions of the present invention are beneficial and can be used for the treatment and / or prevention of mental disorders or disorders selected from depression and treatment-resistant depression, bipolar disorder, post-traumatic stress disorder, obsessive-compulsive disorder, autism spectrum disorder, schizophrenia, and anxiety; symptoms of peripheral sensory neuropathy, preferably neuropathic pain and cold allodynia, fibromyalgia, irritable bowel syndrome, migraine, and cluster headache, such as acute and chronic central hypersensitivity disorders; and motor neuron disorders such as spinal muscular atrophy, amyotrophic lateral sclerosis, Parkinson's dystonia and Huntington's dystonia.

[0014] In a first aspect, the present invention provides a compound of formula (I) (also sometimes referred to herein as (R)-2-(substituted sulfonyl)-hexahydropyrrolo[1,2-a]pyrazin-6(2H)-one) and a compound of formula (II) (also sometimes referred to herein as (S)-2-(substituted sulfonyl)-hexahydropyrrolo[1,2-a]pyrazin-6(2H)-one)

Chemical formula

[0015] In a preferred embodiment, the present invention provides a compound of formula (Ia) (which may also be referred to herein as (R)-2-(phenylsulfonyl)-hexahydropyrrolo[! 2-a]pyrazin-6(2H)-one) and a compound of formula (IIa) (which may also be referred to herein as (S)-2-(phenylsulfonyl)-hexahydropyrrolo[! 2-a]pyrazin-6(2H)-one) [Chemical formula] (wherein, R 1 is selected from the group consisting of hydrogen, fluoro, chloro, cyano, trifluoromethyl and methyl, R 2 is independently selected from the group consisting of hydrogen, fluoro, chloro and methyl, R 1 and R 2 independently occupy any two positions on the phenyl ring), and / or a composition comprising their pharmaceutically acceptable solvate or co-crystal, The present invention provides a composition in which the enantiomer excess (ee) of the compound of formula (Ia) is 20% or more and 50% or less.

[0016] In some embodiments of the compositions of the present invention, the enantiomer excess (ee) of the compound of formula (Ia) is 20% or more and 40% or less. In another embodiment, the present invention provides a pharmaceutical composition comprising the composition of the present invention and a pharmaceutically acceptable carrier. In yet another embodiment, the present invention provides a kit of parts comprising a compound of formula (I) and a compound of formula (II), and instructions for combining the compounds of formula (I) and formula (II) to obtain an enantiomer excess (ee) of the compound of formula (I) of 20% or more and 50% or less. In this embodiment, the same preferred range of enantiomer excess (ee) of the compound of formula (I) and the enantiomer ratio of the compound of formula (I) to the compound of formula (II) as described herein apply with respect to the composition.

[0017] In yet another embodiment, the present invention provides a composition of the present invention for use as a pharmaceutical, or a pharmaceutical composition of the present invention, or a kit of the present invention. In yet another embodiment, the present invention provides compositions or pharmaceutical compositions or kits of the present invention for the treatment and / or prevention of mental disorders or disorders selected from typically and preferably depression and treatment-resistant depression, bipolar disorder, post-traumatic stress disorder, obsessive-compulsive disorder, autism spectrum disorder, schizophrenia, and anxiety; symptoms of peripheral sensory neuropathy, preferably peripheral neuropathic pain and cold allodynia, fibromyalgia, irritable bowel syndrome, migraine, and acute and chronic central hypersensitivity disorders such as cluster headache; and motor neuron disorders such as spinal muscular atrophy, amyotrophic lateral sclerosis, Parkinson's dystonia, and Huntington's dystonia. In yet another embodiment, the present invention provides a method for treating and / or preventing mental disorders or disorders selected from typically and preferably depression and treatment-resistant depression, bipolar disorder, post-traumatic stress disorder, obsessive-compulsive disorder, autism spectrum disorder, schizophrenia, and anxiety; symptoms of peripheral sensory neuropathy, preferably peripheral neuropathic pain and cold allodynia, fibromyalgia, irritable bowel syndrome, migraine, and acute and chronic central hypersensitivity disorders such as cluster headache; and motor neuron disorders such as spinal muscular atrophy, amyotrophic lateral sclerosis, Parkinson's dystonia, and Huntington's dystonia.

[0018] In yet another embodiment, the present invention provides the use of compositions of the present invention or pharmaceutical compositions of the present invention or kits of the present invention in the manufacture of pharmaceuticals for the treatment and / or prevention of mental disorders or disorders selected from typically and preferably depression and treatment-resistant depression, bipolar disorder, post-traumatic stress disorder, obsessive-compulsive disorder, autism spectrum disorder, schizophrenia, and anxiety; symptoms of peripheral sensory neuropathy, preferably peripheral neuropathic pain and cold allodynia, fibromyalgia, irritable bowel syndrome, migraine, and acute and chronic central hypersensitivity disorders such as cluster headache; and motor neuron disorders such as spinal muscular atrophy, amyotrophic lateral sclerosis, Parkinson's dystonia, and Huntington's dystonia. In yet another embodiment, the present invention provides a product comprising the composition of the present invention or the pharmaceutical composition of the present invention, a container or package, and written instructions such as a package insert and a dosage instruction sheet. Other aspects and embodiments of the present invention will become apparent as this specification progresses. [Brief explanation of the drawing]

[0019] [Figure 1] This figure shows the effects of the R- and S-enantiomers of 2-(2-fluorobenzenesulfonyl)hexahydropyrrolo[1,2-a]pyrazine-6-one, as well as mixtures of their different enantiomers, on paclitaxel-induced mechanical allodynia. [Figure 2]This figure shows the effects of the R- and S-enantiomers of 2-(2-fluorobenzenesulfonyl)hexahydropyrrolo[1,2-a]pyrazine-6-one, as well as mixtures of their different enantiomers, on paclitaxel-induced mechanoalgesia. [Modes for carrying out the invention]

[0020] Unless otherwise defined, all scientific and technical terms used herein have the same meanings as those generally understood by those skilled in the art to which this invention pertains. When used to characterize the enantiomer excess, the term "approximately" means ±4% with respect to a given number, unless otherwise indicated. In each embodiment of the present invention, the term "approximately" may be omitted. The term "preferably" is used to describe features or embodiments that are not required in the present invention but can produce improved technical effects and are therefore desirable but not essential. Several compounds are described herein by reference to their structural formulas and / or chemical names, such as their IUPAC names. In cases where there is a discrepancy between the structural formula and the chemical name, the present invention clearly relates to the compound referred to by the structural formula and chemical name.

[0021] Where a compound of formula (I) is referred to herein, it should be understood that it also refers to any preferred example of a compound of formula (I), such as a compound of formula (Ia). Furthermore, where a compound of formula (II) is referred to herein, it should be understood that it also refers to any preferred example of a compound of formula (II), such as a compound of formula (IIa). The term “treatment” of a disorder or disease as used herein is well known in the art. “Treatment” of a disorder or disease means that the disorder or disease is suspected or diagnosed in a patient / subject. A patient / subject suspected of having a disorder or disease typically exhibits certain clinical and / or pathological symptoms that a person skilled in the art can readily attribute to a particular condition (i.e., diagnose the disorder or disease). “Treatment” of a disorder or disease can lead, for example, to the cessation of the progression of the disorder or disease (e.g., no worsening of symptoms) or to the delay of the progression of the disorder or disease (if the cessation of progression is only transient). “Treatment” of a disorder or disease can also lead to a partial response (e.g., improvement of symptoms) or a complete response (e.g., disappearance of symptoms) in a subject / patient suffering from the disorder or disease. Therefore, “treatment” of a disorder or disease may also refer to improvement of the disorder or disease, for example, to the cessation or delay of the progression of the disorder or disease. Such partial or complete responses may be followed by relapse. It should be understood that subjects / patients may exhibit broad responses to treatment (such as the exemplary responses described above). Treatment of the disorder or disease includes, among other things, curative treatment (preferably leading to a complete response, and ultimately a cure, of the disorder or disease) and symptomatic treatment (including symptom relief).

[0022] The term “prevention” of a disorder or disease as used herein is also well known in the art. For example, patients / subjects suspected of being susceptible to a disorder or disease may particularly benefit from the prevention of the disorder or disease. Subjects / patients may undergo certain medical procedures that are known to carry the risk of producing undesirable effects, such as the development of peripheral neuropathy symptoms associated with cancer chemotherapy. Subjects / patients may have susceptibility, predisposition, or risk factors for a disorder or disease, including but not limited to genetic predisposition. Such predispositions can be determined, for example, by standard methods or assays using genetic markers or phenotypic indicators. It should be understood that in patients / subjects, a disorder or disease that can be prevented according to the present invention has not been diagnosed or cannot be diagnosed (e.g., the patient / subject does not exhibit any clinical or pathological symptoms). Therefore, the term “prevention” includes the use of the aqueous pharmaceutical composition of the present invention before any clinical and / or pathological symptoms are diagnosed or determined, or can be diagnosed or determined, by the attending physician. With respect to the numerical values ​​described herein, unless otherwise explicitly stated, the last decimal place of the number preferably indicates its precision. Therefore, unless other tolerances are given, the maximum tolerance is preferably determined by applying a rounding rule to the last decimal place. Thus, the value 2.5 preferably includes the range of 2.45 to 2.54.

[0023] The present invention relates to a composition comprising (R)-2-(substituted sulfonyl)-hexahydropyrrolo[1,2-a]pyrazine-6(2H)-one of formula (I) and (S)-2-(substituted sulfonyl)-hexahydropyrrolo[1,2-a]pyrazine-6(2H)-one of formula (II) in a certain ratio. The term “composition” should be understood to mean that the pure compound of formula (I) and the pure compound of formula (II) must not have to be directly mixed. They can be formulated together or separately and administered simultaneously or subsequently. However, the ratio of the compound of formula (I) to the compound of formula (II) obtained in the therapeutic subject is as required by the present invention. Preferably, the composition of the present invention is a mixture of the compound of formula (I) and the compound of formula (II), but the composition of the present invention may also include a combination of one or more articles containing the compound of formula (I) and one or more articles containing the compound of formula (II), or a combination of one or more articles containing the compound of formula (I) and a mixture of the compound of formula (I) and the compound of formula (II), for example, a combination of one or more articles containing a mixture of the compound of formula (I) and the compound of formula (II), such that the ratio of the compound of formula (I) to the compound of formula (II) obtained in the therapeutic subject is as required by the present invention.

[0024] Furthermore, the 2-(substituted sulfonyl)-hexahydropyrrolo[1,2-a]pyrazine-6(2H)-one contained in the composition of the present invention must be present in the entire range of the ratio of compound (I) to compound (II) required in the present invention, or in the entire range expressed as the enantiomer excess of compound (I). In other words, theoretically dividing a composition containing equal amounts of compound (I) and compound (II) into a component containing an excess amount of compound (I) and another component containing an excess amount of compound (II) would be contrary to the spirit of the present invention. Therefore, regardless of the physical form of the composition of the present invention, the composition as a whole must satisfy the requirements regarding the range of the ratio of compound (I) to compound (II) or the range expressed as the enantiomer excess of compound (I). The ratio of compound (I) to compound (II), or expressed as the enantiomer excess of compound (I), should be understood to be based on a statistically significant number of 2-(substituted sulfonyl)-hexahydropyrrolo[1,2-a]pyrazine-6(2H)-one molecules, typically more than 1000 molecules. In this invention, the relative amounts of compound (I) to compound (II) are expressed by the ratio of compound (I) to compound (II), or by the enantiomer excess of compound (I).

[0025] It should be understood that, unless otherwise specified, the “ratio” of compound (I) to compound (II) used herein refers to the mass ratio of compound (I) to compound (II). When solvates of compound (I) and / or compound (II) are used, the solvent is ignored in this calculation. In other words, the “ratio of compound (I) to compound (II)” is calculated as follows: TIFF2022510362000003.tif21146

[0026] As is well known to those skilled in the art, the ratio of compounds differing only in chirality, such as the compound of formula (I) and the compound of formula (II), can be determined by several methods known in the art, including but not limited to chromatography using a chiral retainer, capillary electrophoresis separation on a chiral retainer, optical rotation of polarization rotation, nuclear magnetic resonance spectroscopy using a chiral shift reagent, or derivatization of the compound using a chiral compound such as moscheric acid, followed by chromatography or nuclear magnetic resonance spectroscopy. Furthermore, enantiomers can be isolated from a mixture by methods known to those skilled in the art, including chiral high-pressure liquid chromatography (HPLC) and direct fractional crystallization of racemates, by chiral cocrystallization techniques that utilize the formation of specific hydrogen bonding interactions present in the cocrystal (see Springuel GR, et al., 2012; and U.S. Patent No. 6,570,036). Useful cocrystallization partners include enantiomers of mandelic acid, malic acid, tartaric acid and their derivatives, or enantiomers can be prepared by asymmetric synthesis. (See, for example, Eliel and Wilen, 1994.)

[0027] The ratio (sometimes called chiral purity) of the compound of formula (I) to the compound of formula (II) in the composition of the present invention, such as a non-racemic mixture, is typically and preferably determined by chiral HPLC (see example for details), and the equation is: ee=(A R -A S ) / (A R +A S ) × 100% It can also be calculated and expressed as the enantiomer excess (ee). In the formula, A R This is the peak area of ​​the compound of formula (I) in the HPLC chromatogram of the sample solution, and A S This represents the peak area of ​​the compound of formula (II) in the HPLC chromatogram of the sample solution. In this regard, while chiral "purity" has been mentioned above, it is recognized that the gist of the present invention is not to achieve high chiral purity of the compound of formula (I) or the compound of formula (II). Rather, the gist of the present invention is that a certain range of ratios between the compound of formula (I) and the compound of formula (II) produces a particularly synergistic effect. In contrast to cases where the purity of a compound should simply be improved, i.e., where the objective is known, i.e., to obtain a particular compound with ideally 100% purity, the present invention is based on two compounds in a previously unknown ratio, namely the compound of formula (I) and the compound of formula (II).

[0028] In the present invention, "linear, branched, or cyclic C 1-4 The term "-alkyl group" refers to any alkyl group having 1 to 4 carbon atoms. Examples include methyl, ethyl, 1-propyl, 2-propyl, 1-butyl, 2-butyl, iso-butyl, and tert-butyl. "Linear, branched, or cyclic C groups which may be substituted with one or more F atoms" 1-4 The term "-alkyl group" refers to a linear, branched, or cyclic C group. 1-4 The "-alkyl group" may be substituted with one or more fluorine atoms, which typically replace the hydrogen atoms of the alkyl group. The number of fluorine atoms is not particularly limited, but is typically 1 to 10, i.e., 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10. Examples include trifluoromethyl and 1-trifluoromethyl-2,2,2-trifluoroethyl.

[0029] The phrase "independently occupies any two positions on the phenyl ring" indicates that the group may be bonded (or connected) to any available position on the phenyl ring. Typically, the group is bonded to the phenyl group, replacing a hydrogen atom at that position. Therefore, the ring carbon atoms of the phenyl ring, instead of being bonded to a hydrogen atom (for example, R 1 or R 2 ) is bonded to the base. 1 R 2It should be understood that this is not an essential substituent. Therefore, the phenyl ring is R 1 Or R 2 , or both may be substituted, or R 1 But R 2 However, substitution is not required. 1 and R 2The substituted phenyl ring may be bonded at any available position, such as ortho, meta, or pata. Specific examples of substituted phenyl rings include 2-fluorophenyl-, 2-chlorophenyl-, 2-methylphenyl-, 2-cyanophenyl-, 2-trifluoromethylphenyl-, 3-fluorophenyl-, 3-chlorophenyl-, 3-methylphenyl-, 3-cyanophenyl-, 3-trifluoromethylphenyl-, 4-fluorophenyl-, 4-chlorophenyl-, 4-methylphenyl-, 4-cyanophenyl-, 4-trifluoromethylphenyl-, 2,3-difluorophenyl-, 2-fluoro-3-chlorophenyl-, 2- Fluoro-3-methylphenyl-, 2-fluoro-3-cyanophenyl-, 2-fluoro-3-trifluoromethylphenyl-, 2,4-difluorophenyl-, 2-fluoro-4-chlorophenyl-, 2-fluoro-4-methylphenyl-, 2-fluoro-4-cyanophenyl-, 2-fluoro-5-trifluoromethylphenyl-, 2,5-difluorophenyl-, 2-fluoro-5-chlorophenyl-, 2-chloro-5-methylphenyl-, 2-fluoro-5-cyanophenyl-, 2-fluoro-5-trifluoromethyl Phenyl-, 2,6-difluorophenyl-, 2-fluoro-6-chlorophenyl-, 2-fluoro-6-methylphenyl-, 2-fluoro-6-cyanophenyl-, 2-fluoro-6-trifluoromethylphenyl-, 2-chloro-3-fluorophenyl-, 2,3-dichlorophenyl-, 2-chloro-3-methylphenyl-, 2-chloro-3-cyanophenyl-, 2-chloro-3-trifluoromethylphenyl-, 2-chloro-4-fluorophenyl-, 2,4-dichlorophenyl-, 2-chloro-4-methylphenyl-, 2-chloro-4-cyanophenyl-, 2-chloro-5-trifluoromethylphenyl-, 2-chloro-5-fluorophenyl-, 2,5-dichlorophenyl-, 2-chloro-5-methylphenyl-, 2-chloro-5-cyanophenyl-, 2-chloro-5-trifluoromethylphenyl-, 2,6-dichlorophenyl-, 2-chloro-6-methylphenyl-, 2-chloro-6-cyanophenyl-, 2-chloro-6-trifluoromethylphenyl-, 2-methyl-3-fluorophenyl-, 2-methyl-3-chlorophenyl-, 2,3-dimethylphenyl-, 2-methyl-3-cyanophenyl-, 2-methyl-3-trifluoromethylphenyl-, 2-methyl-4-fluorophenyl-, 2-methyl-4-chlorophenyl-, 2,4-dimethylphenyl-, 2-methyl-4-cyanophenyl-, 2-methyl-4-trifluoromethylphenyl-, 2-methyl-5-fluorophenyl-, 2-methyl-5-chlorophenyl-, 2,5-dimethylphenyl-, 2-methyl-5-cyanophenyl-, 2-methyl-5-tri Fluoromethylphenyl-, 2,6-dimethylphenyl-, 2-methyl-6-cyanophenyl-, 2-methyl-6-trifluoromethylphenyl-, 2-cyano-3-fluorophenyl-, 2-cyano-3-chlorophenyl-, 2-cyano-3-methylphenyl-, 2-cyano-4-fluorophenyl-, 2-cyano-4-chlorophenyl-, 2-cyano-4-methylphenyl-, 2-cyano-5-fluorophenyl-, 2-cyano-5-chlorophenyl-, 2-cyano-5-methyl Phenyl-,2-trifluoromethyl-3-fluorophenyl-,2-trifluoromethyl-3-chlorophenyl-,2-trifluoromethyl-3-methylphenyl-,2-trifluoromethyl-4-fluorophenyl-,2-trifluoromethyl-4-chlorophenyl-,2-trifluoromethyl-4-methylphenyl-,2-trifluoromethyl-5-fluorophenyl-,2-trifluoromethyl-5-chlorophenyl-,2-trifluoromethyl-5-methylphenyl-,3,4-difluorophenyl-,3-fluoro-4-chlorophenyl-,3-fluoro-4-methylphenyl-,3-fluoro-4-cyanophenyl-,3-fluoro-4-trifluoromethylphenyl-,3-chloro-4-fluorophenyl-,3,4-dichlorophenyl-,3-chloro-4-methylphenyl-,3-chloro-4-cyanophenyl-,3-chloro-4-trifluoromethylphenyl-,3-methyl-4-fluorophenyl-,3-methyl-4-chlorophenyl-,3,Examples include the group consisting of 4-dimethylphenyl-, 3-methyl-4-cyanophenyl-, 3-methyl-4-trifluoromethylphenyl-, 3-cyano-4-fluorophenyl-, 3-cyano-4-chlorophenyl-, 3-cyano-4-methylphenyl-, 3-trifluoromethyl-4-fluorophenyl-, 3-trifluoromethyl-4-chlorophenyl-, 3-trifluoromethyl-4-methylphenyl-, 3,5-difluorophenyl-, 3-fluoro-5-chlorophenyl-, 3-fluoro-5-methylphenyl-, 3-fluoro-5-cyanophenyl-, 3-fluoro-5-trifluoromethylphenyl-, 3,5-dichlorophenyl-, 3-chloro-5-methylphenyl-, 3-chloro-5-cyanophenyl-, 3-chloro-5-trifluoromethylphenyl-, 3,5-dimethylphenyl-, 3-methyl-5-cyanophenyl-, and 3-methyl-5-trifluoromethylphenyl-.

[0030] In a preferred embodiment, the (substituted) phenyl ring is a group selected from phenyl, 2-fluorophenyl, 3-fluorophenyl, and 4-fluorophenyl. More preferably, the (substituted) phenyl ring is a group selected from phenyl, 2-fluorophenyl, and 4-fluorophenyl. Even more preferably, the (substituted) phenyl ring is a group selected from phenyl and 2-fluorophenyl.

[0031] The term "pharmaceutically acceptable" indicates that a compound or composition, typically and preferably a solvate, cocrystal, or support, must be chemically or toxicologically compatible with other components, typically and preferably the composition of the present invention, when used typically and preferably in a formulation, or when used to treat animals, preferably humans. Preferably, the term "pharmaceutically acceptable" indicates that a compound or composition, typically and preferably a solvate, cocrystal, or support, must be chemically and toxicologically compatible with other components, typically and preferably the composition of the present invention, when used typically and preferably in a formulation, or when used to treat animals, preferably humans. Pharmaceutical compositions are described in "Remington: The Science and Practice of Pharmacy", Pharmaceutical Press, 22. nd It is recognized that the formulation can be manufactured using techniques that are publicly known to those skilled in the art, such as the techniques published in the edition.

[0032] A "solvate" refers to an association or complex of one or more solvent molecules with the (R)-enantiomer of formula (I) or the (S)-enantiomer of formula (II). Examples of solvents that form solvates include, but are not limited to, water, isopropanol, ethanol, methanol, dimethyl sulfoxide (DMSO), ethyl acetate, acetic acid, and ethanolamine. The term "hydrate" refers to a complex in which the solvent molecule is water.

[0033] A "cocrystal" refers to a crystalline structure comprising at least two different compounds that are solid in their pure form under ambient conditions. The at least two different compounds may include the compound of formula (I) and / or the compound of formula (II) and / or any other component of the composition or an excipient of the pharmaceutical composition. The cocrystal is prepared from neutral molecular species, and all species remain neutral after crystallization. Furthermore, they are typically and preferably crystalline homogeneous phase materials in which two or more building compounds exist in defined stoichiometric ratios. In this regard, see Wang Y and Chen A, 2013; and Springuel GR, et al., 2012; and U.S. Patent No. 6,570,036. It should be understood that the compound of formula (I) and / or the compound of formula (II) may exist in the form of either polymorph. Various cocrystals and techniques for preparing such cocrystals are described in RSC Drug Discovery, Pharmaceutical Salts and Co-crystals, published in 2012 by the Royal Society of Chemistry and edited by Johan Wouters and Luc Quere, in particular in chapters 15 and 16. Preferred examples of cocrystal-forming agents are disclosed in Table 16.1 of this reference. More preferred cocrystals include cocrystals of α-hydroxy acids, α-keto acids and / or α-ketoamides with compounds of formulas (I) and (II) in the (R) and (S) ratios disclosed herein.Examples of α-hydroxy acids include atrolactinic acid, benzyl acid, 4-chloromandelic acid, citric acid, 3,4-dihydroxymandelic acid, ethyl pyruvate, galacturonic acid, gluconolactone, glucuronic acid, glucuronolactone, glycolic acid, 2-hydroxybutanoic acid, 2-hydroxypentanoic acid, 2-hydroxyhexanoic acid, 2-hydroxyheptanoic acid, 2-hydroxyoctanoic acid, 2-hydroxynonanoic acid, 2-hydroxydecanoic acid, 2-hydroxyundecanoic acid, 4-hydroxymandelic acid, and 3-hydroxy Examples include droxy-4-methoxymandelic acid, 4-hydroxy-3-methoxymandelic acid, α-hydroxyarachidonic acid, α-hydroxybutyric acid, α-hydroxyisobutyric acid, α-hydroxylauric acid, α-hydroxymyristic acid, α-hydroxypalmitic acid, α-hydroxystearic acid, 3-(2'-hydroxyphenyl)lactic acid, 3-(4'-hydroxyphenyl)lactic acid, lactic acid, malic acid, mandelic acid, methyllactic acid, methylpyrubate, mucoic acid, α-phenylacetic acid, α-phenylpyruvic acid, pyruvic acid, sugar acid, tartaric acid, and tartonic acid. Examples of α-keto acids include 2-ketoethaneic acid (glyoxylic acid), methyl 2-ketoethaneate, 2-ketopropanoic acid (pyruvic acid), methyl 2-ketopropanoate (methyl pyruvate), ethyl 2-ketopropanoate (ethyl pyruvate), propyl 2-ketopropanoate (propyl pyruvate), 2-phenyl-2-ketoethaneic acid (benzoyl benzoate), methyl 2-phenyl-2-ketoethaneate (methyl benzoyl benzoate), and ethyl 2-phenyl Examples include 2-ketoethanoate (ethyl benzoylmate), 3-phenyl-2-ketopropanoic acid (phenylpyruvic acid), methyl 3-phenyl-2-ketopropanoate (methylphenylpyrubate), ethyl 3-phenyl-2-ketopropanoate (ethylphenylpyrubate), 2-ketobutanoic acid, 2-ketopentanoic acid, 2-ketohexanoic acid, 2-ketoheptanoic acid, 2-ketooctanoic acid, 2-ketododecanoic acid, and methyl 2-ketooctanoate. Examples of α-ketoamides include any compound that can be obtained by reacting any one of the above examples of α-keto acids with a primary or secondary amine.

[0034] In a first embodiment, the present invention relates to a compound of formula (I) and a compound of formula (II). [ka] (In the formula, Z is, Linear, branched, or cyclic carbon atoms may be substituted with one or more F atoms. 1-4 - Alkyl alkyl group, or R 1 or R 2 Phenyl groups substituted with Selected from, R 1 R is selected from the group consisting of hydrogen, fluoro, chloro, cyano, trifluoromethyl, and methyl. 2 These are independently selected from the group consisting of hydrogen, fluoro, chloro, and methyl. R 1 and R 2 (These independently occupy any two positions on the phenyl ring.) A composition comprising and / or pharmaceutically acceptable solvates or cocrystals thereof, The present invention provides a composition having an enantiomer excess (ee) of the compound of formula (I) of the above formula of 20% or more and 50% or less.

[0035] In a preferred embodiment, the present invention relates to a compound of formula (Ia) and a compound of formula (IIa). [ka] (In the formula, R 1 R is selected from the group consisting of hydrogen, fluoro, chloro, cyano, trifluoromethyl, and methyl. 2 These are independently selected from the group consisting of hydrogen, fluoro, chloro, and methyl. R 1 and R 2 (These independently occupy any two positions on the phenyl ring.) A composition comprising and / or pharmaceutically acceptable solvates or cocrystals thereof, The present invention provides a composition in which the enantiomer excess (ee) of the compound of formula (Ia) is 20% or more and 50% or less.

[0036] Preferably, R 1 R is hydrogen, methyl, or fluoro. More preferably, 1 R is fluoro. 2 The element is preferably hydrogen, fluoro, or methyl, more preferably hydrogen or fluoro, and even more preferably hydrogen. More preferred compositions are non-racemic mixtures of 2-(2-fluorophenyl)sulfonyl-hexahydropyrrolo[1,2-a]pyrazine-6(2H)-one, non-racemic mixtures of 2-(3-fluorophenyl)sulfonyl-hexahydropyrrolo[1,2-a]pyrazine-6(2H)-one, or non-racemic mixtures of 2-(4-fluorophenyl)sulfonyl-hexahydropyrrolo[1,2-a]pyrazine-6(2H)-one, wherein the enantiomer excess of the corresponding (R) enantiomer in these more preferred embodiments is 20% or more and 50% or less. These compositions, as well as any other compositions and pharmaceutical compositions according to the present invention, preferably induced by NMDA + glycine from rat spinal cord synaptosomes. 3It inhibits the release of 1H]-D-aspartate by at least about 36%, preferably at least about 40%, more preferably at least about 45%, and even more preferably about 50% at a concentration of about 10 nM. Assays for measuring this parameter are described in Bonanno G et al. Heterocarrier-mediated reciprocal modulation of glutamate and glycine release in rat cerebral cortex and spinal cord synaptosomes. Eur J Pharmacol 1994, 252(1):61-7; and Fariello RG, Ghelardini C, Di Cesare Mannelli L, Bonanno G, Pittaluga A, Milanese M, Misiano P, Farina C. Broad spectrum and prolonged efficacy of dimiracetam in models of neuropathic pain. Neuropharmacology. 2014 Jun;81:85-94. PMID: 24486381.

[0037] In the composition according to the present invention, the compound of formula (I) and the compound of formula (II) preferably differ only in the stereochemistry of the stereocenters shown in formulas (I) and (II). In other words, the composition according to the present invention preferably contains the compound of formula (I) and the compound of formula (II), where Z is the same in the compound of formula (I) and the compound of formula (II). Typically, non-solvated or non-cocrystalline compositions are preferred. More preferably, non-solvated and non-cocrystalline compositions are preferred. Accordingly, in another embodiment, the present invention provides compositions comprising a compound of formula (I) and a compound of formula (II) in an enantiomer excess (ee) of the compound of formula (I) of 20% or more and 50% or less. More preferably, the enantiomer excess (ee) of the compound of formula (I) is 20% or more and about 40% or less. Even more preferably, the enantiomer excess (ee) of the compound of formula (I) is 20% or more and 35% or less.

[0038] The enantiomer excess (ee) of the compound of formula (I) is preferably 22%, 24%, 26%, 28%, 30%, 32%, 34%, 36%, 38%, or 40% or more. On the other hand, the enantiomer excess (ee) of the compound of formula (I) can preferably be 48%, 46%, 44%, 42%, 40%, 38%, 36%, 34%, 32%, or 30% or less. Suitable and preferred ranges for the enantiomer excess (ee) of the compound of formula (I) include 20%~48%, 20%~46%, 20%~44%, 20%~42%, 20%~40%, 20%~38%, 20%~36%, 20%~34%, 20%~32%, 20%~30%, 30%~50%, 30%~48%, 30%~46%, 30%~44%, 30%~42%, 30%~40%, 40%~50%, 25%~45%, 25%~40%, 25%~35%, 35%~50%, 35%~45%, and 35%~40%. As is known to those skilled in the art, the ratio of compound (I) to compound (II) can be referred to instead of the enantiomer excess. A preferred range for the ratio of compound (I) to compound (II) is 1.5:1 to 3.0:1, preferably 1.5:1 to 2.3:1, and more preferably 1.5:1 to 2.0:1. Another preferred range for the ratio of compound (I) to compound (II) is 1.5:1 to 3.3:1, preferably 2:1 to 3:1, and more preferably 2:1 or 3:1.

[0039] In another embodiment, the present invention provides a pharmaceutical composition comprising the composition of the present invention and a pharmaceutically acceptable carrier. In another embodiment, the present invention provides a kit of parts comprising a compound of formula (I) and a compound of formula (II), and instructions for combining the compounds of formula (I) and formula (II) to obtain an enantiomer excess (ee) of the compound of formula (I) of 20% or more and 50% or less. Wherever the use of the compositions of the present invention is described below, it should be understood that the kit according to the present invention may be used instead. Those skilled in the art will understand that the components of the kit may be combined before administration, which is preferable, or the components of the kit may be administered separately. In the latter case, in order to achieve the effects of the present invention, the components of the kit should typically be administered within a time range of at most 30 minutes.

[0040] In yet another embodiment, the present invention provides a composition of the present invention for use as a pharmaceutical, or a pharmaceutical composition of the present invention, or a kit of the present invention. In yet another embodiment, the present invention provides compositions or pharmaceutical compositions or kits for use in the treatment or prevention of numerous diseases and disorders, including those described below: a) For the prevention or treatment of positive symptoms of peripheral neuropathy, including cold sensitivity, tingling, burning, or throbbing sensations, including primary allodynia, secondary allodynia, or other pain or discomfort associated with sensitization of the spinal cord or higher brain structures or neuronal pathways, as well as those associated with chemotherapy, bacterial growth inhibitory therapy, viral infection and treatment, postherpetic neuralgia, osteonecrosis, trigeminal neuralgia, or diabetic peripheral neuropathy; b) For the prevention or treatment of pain, including bone and joint pain, osteonecrosis pain, repetitive pain, toothache, dysmenorrhea pain, cancer pain, myofascial pain, surgical pain, perioperative pain, and postoperative pain syndromes such as post-mastectomy syndrome, post-thoracotomy syndrome, or stump pain, as well as pain associated with the angina, neuromatous pain, complex regional pain syndrome, chronic pelvic pain, and chronic low back pain; c) For the prevention or treatment of inflammatory pain such as osteoarthritis, rheumatoid arthritis, rheumatic diseases, chronic arthritis pain and associated neuralgia, tenosynovitis, and gout; d) For the prevention or treatment of neuropathic pain such as chemotherapy-induced pain, post-traumatic injury pain, contusion pain, painful traumatic mononeuropathy, painful polyneuropathy, spinal injury, low back pain, pain resulting from nerve compression or constriction, sacral pain, trigeminal neuralgia, migraine, postherpetic neuralgia, phantom limb pain, postherpetic pain, diabetic neuropathy, and central pain syndromes caused by lesions at any level of the peripheral nervous system; e) For the prevention or treatment of neuropsychiatric disorders. Examples of neuropsychiatric disorders include schizophrenia, psychosis including schizophrenia, schizophrenia-like disorders, schizoaffective disorder, delusional disorder, short-term psychotic disorder, substance-related disorders, paranoid schizophrenia, disorganized schizophrenia, catatonic schizophrenia or schizophrenia that is difficult to classify, substance-induced psychotic disorders, substance-related disorders and addictive behaviors; f) Focal and generalized epilepsy and other seizures; g) Obesity or other eating disorders associated with excessive food intake, bulimia nervosa; h) Brain damage resulting from stroke, hydrocephalus, cerebral ischemia, cerebral hemorrhage, neurodegenerative diseases, cardiac bypass surgery and transplantation, perinatal hypoxia, cardiac arrest, and hypoglycemic brain injury; i) Sleep disorders such as insomnia, narcolepsy, or restlessness of the lower limbs; j) Anxiety disorders such as mood disorders, panic attacks, panic disorder, acute stress disorder, agoraphobia, generalized anxiety disorder, obsessive-compulsive disorder, post-traumatic stress disorder, separation anxiety disorder, social phobia, specific phobias, and substance-induced anxiety disorder; k) Mood disorders such as depression, anemia, unipolar depression, bipolar disorder, and psychotic depression; l) Substance addiction, drug dependence, and substance tolerance, dependence, or withdrawal, including alcohol, amphetamines, cannabis, cocaine, hallucinogens, inhalants, nicotine, opioids, phencyclidine, sedatives, hypnotics, or anxiolytics; m) Cognitive impairment such as age-related cognitive decline or cognitive impairment associated with Alzheimer's disease, ischemia, trauma, vascular problems or stroke, HIV disease, Parkinson's disease, Huntington's disease, Pick's disease, Creutzfeldt-Jakob disease, chemotherapy, perinatal hypoxia, other medical conditions or substance abuse; n) Parkinson's disease, including drug-induced parkinsonism, or post-encephalitis parkinsonism; o) Attention deficit disorders such as attention deficit hyperactivity disorder (ADHD), obsessive-compulsive disorder, phobias, post-traumatic stress disorder, autism and autism spectrum disorder, and impulse control disorders; p) Tinnitus, age-related hearing loss; q) To enhance learning and memory; r) For the prevention or treatment of hereditary or sporadic motor neuron disorders. Examples include amyotrophic lateral sclerosis, primary lateral sclerosis, progressive muscular atrophy, progressive bulbar palsy, Friedreich's ataxia, and fragile X syndrome; s) For the prevention or treatment of motor disorders. Examples include dystonia, chorea including Huntington's disease, Parkinson's disease-associated dystonia, Creutzfeldt-Jakob disease, progressive supranuclear palsy, multiple system atrophy, corticobasal degeneration, and basal ganglia calcification; t) Due to akinesia such as akinesia rigidity syndrome, u) Drug-induced parkinsonism such as neuroleptic-induced parkinsonism, neuroleptic malignant syndrome, neuroleptic-induced acute dystonia, neuroleptic-induced acute sitting distress, neuroleptic-induced tardive dyskinesia, and drug-induced postural tremor, including resting tremor, postural tremor and intention tremor, chorea (Sydenham's chorea, Huntington's disease, benign hereditary chorea, neuroacanthocytosis, symptomatic chorea, drug-induced chorea and hemivalism, etc.), generalized or focal myoclosis For dyskinesia such as tics (including simple tics, complex tics and symptomatic tics), dystonia (including generalized dystonia such as idiopathic dystonia, drug-induced dystonia, symptomatic dystonia and paroxysmal dystonia, as well as focal dystonia such as blepharospasm, maxillofacial dystonia, spasmodic dysphonia, spasmodic torticollis, axial dystonia, writer's cramp and hemiplegic dystonia), muscle spasms, and disorders related to muscle spasms or weakness, including tremors; v) for urinary incontinence, multiple system atrophy, tuberous sclerosis, olivopontocerebellar atrophy, cerebral palsy, drug-induced optic neuritis, ischemic retinopathy, diabetic retinopathy, glaucoma, spasticity, myoclonus, and dyskinesia associated with Tourette syndrome. The above list of diseases is provided merely as examples and should not be interpreted as limiting the present invention. Of the above, one or more selected from a), e), q), r), and s) are preferred.

[0041] The disease or disorder is typically and preferably selected from peripheral sensory neuropathy, preferably peripheral neuropathic pain and other symptoms of peripheral sensory neuropathy; as well as neuropsychiatric states such as seizures; depression; or cognitive impairment; and motor neuron diseases such as amyotrophic lateral sclerosis. Furthermore, the compositions of the present invention can also be used, for example, in a non-therapeutic form, to enhance learning and memory in healthy subjects. In yet another embodiment, the present invention provides a method for treating and / or preventing a disease or disorder, wherein the disease or disorder is typically and preferably selected from peripheral sensory neuropathy, preferably peripheral neuropathic pain and other symptoms of peripheral sensory neuropathy; as well as neuropsychiatric states such as seizures; depression; or cognitive impairment; and motor neuron diseases such as amyotrophic lateral sclerosis, and the method comprises the step of administering a composition of the present invention, a pharmaceutical composition of the present invention, or a kit of the present invention.

[0042] Part of the present invention also provides a method for treating a disease or disorder, wherein a therapeutically effective amount of the composition or pharmaceutical composition or kit of the present invention is administered to an animal in need, preferably a human. Herein, “therapeutically effective amount” means an amount sufficient to modulate one or more symptoms of the condition or disease to be treated, preferably between 10 mg and 3000 mg per dose, administered orally once, twice, or three times daily. Furthermore, part of the present invention also provides a method for preventing a disease or disorder, wherein a therapeutically effective amount of the composition or pharmaceutical composition or kit of the present invention is administered to an animal in reasonable expectation of needing it, preferably a human. Herein, “therapeuticly effective amount” means an amount sufficient to modulate one or more expected symptoms of the condition or disease to be avoided, preferably between 10 mg and 3000 mg per dose, administered orally once, twice, or three times daily. In yet another embodiment, the present invention provides the use of a composition of the present invention or a pharmaceutical composition of the present invention or a kit of the present invention in the manufacture of a pharmaceutical for use in the treatment and / or prevention of a disease or disorder, wherein the disease or disorder is typically and preferably selected from peripheral sensory neuropathy, preferably peripheral neuropathic pain and other symptoms of peripheral sensory neuropathy; as well as neuropsychiatric states such as seizures; depression; or cognitive impairment; and motor neuron diseases such as amyotrophic lateral sclerosis.

[0043] Part of the present invention also involves administering the composition or pharmaceutical composition of the present invention together with active ingredients and activators, particularly antitumor agents and antiviral agents, which exhibit side effects of peripheral neuropathic pain and other symptoms of peripheral neuropathy. The composition or pharmaceutical composition or kit is preferably used alone or in combination with at least one antitumor agent or at least one antiviral agent. More preferably, the composition or pharmaceutical composition or kit is used alone. More preferably, the composition or pharmaceutical composition or kit is used in combination with at least one antitumor agent. Alternatively, preferably, the composition or pharmaceutical composition or kit is used in combination with at least one antiviral agent. The composition or pharmaceutical composition or kit is more preferably administered in conjunction with at least one antitumor agent or at least one antiviral agent, wherein the administration of the composition or pharmaceutical composition in conjunction with the at least one antitumor agent or at least one antiviral agent is parallel, simultaneous, sequential, or separate administration.

[0044] Such antitumor drugs, though not limited to certain examples, are selected from the group consisting of kinase inhibitors, proteasome inhibitors, taxanes, vinca alkaloids, and platinum salts. Such antiviral drugs, though not limited to certain examples, are selected from nucleoside analogs or nucleotide analogs. It is even more preferable that the antitumor drugs are selected from the group consisting of kinase inhibitors, proteasome inhibitors, taxanes, vinca alkaloids, and platinum salts. The antitumor drugs are preferably selected from sorafenib, sunitinib, afatinib, axitinib, vandetanib, vemurafenib, ixazomib, bortezomib, paclitaxel, docetaxel, cabazitaxel, vincristine, vinblastine, vindesine, vinorelbine, nedaplatin, lovaplatin, picoplatin, satraplain, cisplatin, carboplatin, and oxaliplatin. The antiviral agent is preferably selected from zalcitabine, didanosine, stabudine, and zidovudine.

[0045] The composition or pharmaceutical composition or kit is preferably used with at least one antiviral agent, the antiviral agent preferably selected from nucleosides or nucleotides, and more preferably selected from zalcitabine, didanosine, stabudine, or zidovudine. The disease or disorder is preferably a seizure. Alternatively, the disease or disorder is preferably depression. More preferably, the disease or disorder is cognitive impairment. Even more preferably, the disease or disorder is peripheral sensory neuropathy. Even more preferably, the disease or disorder is peripheral neuropathic pain. The disease or disorder is more preferably a peripheral sensory neuropathy, and the peripheral sensory neuropathy is (i) diabetic neuropathy, (ii) postherpetic neuropathy, (iii) lower back pain, (iv) sacral pain, (v) surgical pain, (vi) crush injury, (vii) spinal injury, (viii) complex regional pain syndrome, (ix) phantom limb sensation, (x) peripheral sensory neuropathy associated with osteoarthritis, (xi) peripheral sensory neuropathy associated with rheumatoid arthritis, (xii) peripheral sensory neuropathy associated with autoimmune osteoarthritis The following are selected from the group consisting of (xiii) headache, (xiv) fibromyalgia, (xv) peripheral sensory neuropathy induced by bacterial growth inhibitory therapy, (xvi) peripheral sensory neuropathy induced by chemotherapeutic agents, (xvii) peripheral sensory neuropathy associated with visceral injury, (xviii) peripheral sensory neuropathy associated with osteonecrosis, (xix) peripheral sensory neuropathy associated with human immunodeficiency virus infection, and (xx) peripheral sensory neuropathy induced by antiviral agents.

[0046] The disease or disorder is preferably a peripheral sensory neuropathy, and the peripheral sensory neuropathy is (i) diabetic neuropathy, (ii) postherpetic neuropathy, (iii) low back pain, (iv) sacral pain, (v) surgical pain, (vi) crush injury, (vii) spinal injury, (viii) complex regional pain syndrome, (ix) phantom limb sensation, (x) peripheral sensory neuropathy associated with osteoarthritis, (xi) peripheral sensory neuropathy associated with rheumatoid arthritis, (xii) peripheral sensory neuropathy associated with autoimmune osteoarthritis, (xi ii) selected from the group consisting of headache, (xiv) fibromyalgia, (xv) peripheral sensory neuropathy induced by bacterial growth inhibitory therapy, (xvi) peripheral sensory neuropathy induced by chemotherapeutic agents, (xvii) peripheral sensory neuropathy associated with visceral injury, (xviii) peripheral sensory neuropathy associated with osteonecrosis, (xix) peripheral sensory neuropathy associated with human immunodeficiency virus infection, (xx) peripheral sensory neuropathy induced by antiviral agents, and (xxi) peripheral neuropathic pain.

[0047] The disease or disorder is more preferably a peripheral sensory neuropathy, and the peripheral sensory neuropathy is diabetic neuropathy. The disease or disorder is more preferably a peripheral sensory neuropathy, and the peripheral sensory neuropathy is postherpetic neuropathy. The disease or disorder is preferably a peripheral sensory neuropathy, and the peripheral sensory neuropathy is lower back pain. The disease or disorder is more preferably a peripheral sensory neuropathy, and the peripheral sensory neuropathy is sacral pain. The disease or disorder is more preferably a peripheral sensory neuropathy, and the peripheral sensory neuropathy is surgical pain. The disease or disorder is more preferably a peripheral sensory neuropathy, and the peripheral sensory neuropathy is crush injury. The disease or disorder is more preferably a peripheral sensory neuropathy, and the peripheral sensory neuropathy is spinal injury. The disease or disorder is more preferably a peripheral sensory neuropathy, and the peripheral sensory neuropathy is complex regional pain syndrome. The disease or disorder is more preferably a peripheral sensory neuropathy, and the peripheral sensory neuropathy is phantom limb sensation. The disease or disorder is more preferably a peripheral sensory neuropathy, and the peripheral sensory neuropathy is peripheral sensory neuropathy associated with osteoarthritis. The disease or disorder is more preferably a peripheral sensory neuropathy, and the peripheral sensory neuropathy is peripheral sensory neuropathy associated with rheumatoid arthritis. The disease or disorder is more preferably a peripheral sensory neuropathy, and the peripheral sensory neuropathy is peripheral sensory neuropathy associated with autoimmune osteoarthritis. The disease or disorder is more preferably a peripheral sensory neuropathy, and the peripheral sensory neuropathy is headache. The disease or disorder is more preferably a peripheral sensory neuropathy, and the peripheral sensory neuropathy is fibromyalgia. The disease or disorder is more preferably a peripheral sensory neuropathy, and the peripheral sensory neuropathy is a peripheral sensory neuropathy induced by bacterial growth inhibitory therapy. The disease or disorder is more preferably a peripheral sensory neuropathy, and the peripheral sensory neuropathy is a peripheral sensory neuropathy induced by a chemotherapeutic agent.The disease or disorder is more preferably a peripheral sensory neuropathy, wherein the peripheral sensory neuropathy is a peripheral sensory neuropathy associated with visceral injury. The disease or disorder is more preferably a peripheral sensory neuropathy, wherein the peripheral sensory neuropathy is a peripheral sensory neuropathy associated with osteonecrosis. The disease or disorder is more preferably a peripheral sensory neuropathy, wherein the peripheral sensory neuropathy is a peripheral sensory neuropathy associated with human immunodeficiency virus infection. The disease or disorder is more preferably a peripheral sensory neuropathy, wherein the peripheral sensory neuropathy is a peripheral sensory neuropathy induced by an antiviral agent. The disease or disorder is more preferably a peripheral sensory neuropathy, wherein the peripheral sensory neuropathy is a peripheral neuropathic pain. The peripheral sensory neuropathy is preferably selected from peripheral sensory neuropathy induced by a chemotherapeutic agent or peripheral sensory neuropathy induced by an antiviral agent.

[0048] The disease or disorder is more preferably a peripheral sensory neuropathy induced by a chemotherapeutic agent, and typically and preferably, the chemotherapeutic agent is selected from the group consisting of kinase inhibitors, proteasome inhibitors, taxanes, vinca alkaloids, and platinum salts. More preferably, the disease or disorder is a peripheral sensory neuropathy induced by a chemotherapeutic agent, and the chemotherapeutic agent is selected from the group consisting of sorafenib, sunitinib, afatinib, axitinib, vandetanib, vemurafenib, ixazomib, bortezomib, paclitaxel, docetaxel, cabazitaxel, vincristine, vinblastine, vindesine, vinorelbine, nedaplatin, lobaplatin, picoplatin, satraplain, cisplatin, carboplatin, or oxaliplatin. More preferably, the peripheral sensory neuropathy is induced by a chemotherapeutic agent, which is sorafenib, paclitaxel, vincristine, cisplatin, carboplatin, or oxaliplatin.

[0049] More preferably, the disease or disorder is a peripheral sensory neuropathy induced by an antiviral agent, and preferably, the antiviral agent is a nucleoside reverse transcriptase inhibitor. Even more preferably, the disease or disorder is a peripheral sensory neuropathy induced by an antiviral agent, and the antiviral agent is selected from zalcitabine, didanosine, stabudine, or zidovudine. Even more preferably, the disease or disorder is a peripheral sensory neuropathy induced by zalcitabine. Preferably, the chemotherapy-induced peripheral sensory neuropathy is accompanied by symptoms of allodynia or paresthesia, more preferably allodynia or paresthesia of the hands or feet, and even more preferably allodynia or paresthesia of the hands or feet induced by sorafenib, vincristine, paclitaxel, or carboplatin, cisplatin, or oxaliplatin. More preferably, the peripheral sensory neuropathy is accompanied by pain, paresthesia, paresthesia, or allodynia. More preferably, the composition of the present invention or the pharmaceutical composition of the present invention can be administered prophylactically before the antitumor chemotherapeutic agent component induces peripheral sensory neuropathy and its associated symptoms. More preferably, the composition of the present invention or the pharmaceutical composition of the present invention can be administered intermittently. Furthermore, in the present invention, it is preferable that the composition of the present invention or the pharmaceutical composition of the present invention can be administered in synchronization with the repeated cycle of the antitumor chemotherapy agent component.

[0050] Dosage depends on the route of administration, the severity of the disease, the age and size of the patient or subject, and other factors that are typically considered by the attending physician when determining individual regimens and dose levels for a particular patient or subject. The composition or pharmaceutical composition of the present invention can be administered by any route, including oral, intramuscular, subcutaneous, topical, transdermal, intranasal, intravenous, sublingual, or rectal administration. Typically and preferably, the pharmaceutical composition of the present invention is administered orally in single dose units once, twice, or three times daily, most preferably once or twice daily. In the most preferred embodiment, the composition or pharmaceutical composition of the present invention is administered twice daily. Typically and preferably, the oral dose of the composition or pharmaceutical composition of the present invention is between 10 mg and 3000 mg per dose, more preferably between 20 mg and 2000 mg per dose, and even more preferably between 50 mg and 1000 mg per dose. Typically and preferably, the composition or pharmaceutical composition is administered orally twice a day at a dose between 10 mg and 3000 mg per dose, more preferably between 20 mg and 2000 mg per dose, and even more preferably between 50 mg and 1000 mg per dose.

[0051] The pharmaceutical compositions of the present invention can be prepared by mixing suitably selected pharmaceutically acceptable excipients, vehicles, adjuvants, additives, surfactants, desiccants, or diluents known to those skilled in the art, and can be suitably adapted for oral, parenteral, or topical administration. Typically and preferably, the pharmaceutical compositions of the present invention can be administered in the form of tablets, capsules, sachets, powders, granules, pellets, oral or parenteral solutions, suspensions, suppositories, ointments, creams, lotions, gels, pastes, and / or may contain liposomes, micelles, and / or microspheres. The pharmaceutically acceptable carriers of the pharmaceutical composition of the present invention are, without limitation, any pharmaceutically acceptable excipient, vehicle, adjuvant, additive, surfactant, desiccant, or diluent. Preferred pharmaceutically acceptable carriers are magnesium carbonate, magnesium stearate, talc, lactose, sugar, pectin, dextrin, starch, tragacanth, methylcellulose, sodium carboxymethylcellulose, low-melting-point wax, and cocoa butter. The pharmaceutically acceptable carriers of the present invention may be solid, semi-solid, or liquid.

[0052] Tablets, capsules, or sachets for oral administration are typically supplied in dose units and may contain common excipients such as binders, fillers, diluents, tablet-forming agents, lubricants, cleaning agents, disintegrants, colorants, flavors, and wetting agents. Tablets may be coated according to methods well known in the art. Preferred fillers preferably include or are cellulose, mannitol, lactose, and similar agents. Preferred disintegrants preferably include or are starch derivatives such as starch, polyvinylpyrrolidone, and sodium starch glycolate. Preferred lubricants preferably include or are magnesium stearate, for example. Preferred wetting agents preferably include or are sodium lauryl sulfate. These oral solid compositions can be prepared by conventional mixing, filling, or tableting methods. Repeated mixing operations can disperse the activator in compositions containing large amounts of fillers. These operations are conventional.

[0053] The oral liquid composition may be provided, for example, in the form of an aqueous solution, emulsion, syrup or elixir, or in the form of a dry product to be reconstituted with water or a suitable liquid carrier at the time of use. The liquid composition may contain a suspending agent, such as sorbitol, syrup, methylcellulose, gelatin, hydroxyethylcellulose, carboxymethylcellulose, aluminum stearate gel or hydrogenated edible fat; an emulsifier, such as lecithin, sorbitan monooleate or acacia; a non-aqueous carrier (which may include edible oils), such as almond oil, fractionated coconut oil, oily esters such as glycerin esters, propylene glycol or ethyl alcohol; a preservative, such as p-hydroxybenzoate methyl or propyl or sorbic acid, and, if desired, common additives such as common flavors or colorants. Oral formulations may include common formulations such as tablets or granules, or may be formulated as such. For parenteral administration, liquid dose units containing the composition of the present invention and a sterile carrier can be prepared. Oral formulations may further contain flavor-masking components to optimize the flavor perception of the oral formulation. Examples of such flavor-masking components may be citrus phenyl, licorice phenyl, mint phenyl, grape phenyl, blackcurrant, or eucalyptus-based flavorants, which are known to those skilled in the art. Parenteral solutions are typically prepared by dissolving the compound in a carrier, sterilizing it by filtration, and then filling and sealing it into a suitable vial or ampoule.

[0054] Adjuvants such as local anesthetics, preservatives, and buffers can be added to the pharmaceutical composition. To enhance stability, the composition may be frozen after being filled into vials and water removed under vacuum. Surfactants or water-retaining agents can be advantageously included in the pharmaceutical composition to promote the uniform distribution of the composition of the present invention. Topical formulations may preferably include or be ointments, creams, lotions, gels, rubbers, solutions, pastes, or may contain liposomes, micelles, or microspheres. The subjects to be treated by the compositions or pharmaceutical compositions of the present invention are humans and animals. Preferred animals are livestock, including, but not limited to, guinea pigs, rabbits, horses, donkeys, camels, cattle, sheep, goats, pigs, cattle, dogs, and parrots. More preferred subjects are mammals, and even more preferably humans. In yet another embodiment, the present invention provides a product comprising a composition of the present invention or a pharmaceutical composition of the present invention or a kit of the present invention, a container or package, and written instructions such as a package insert and a dosage instruction sheet.

[0055] Compounds of formula (I) or formula (II), and aniracetam, buribaracetam, sebaracetam, colracetam, dimiracetam, doriracetam, dupracetam, etilacetam / levetiracetam, fasolacetam, imracetam, methylphenylpiracetam, nebracetam, nephiracetam, omberacetam (Nupept), oxyracetam, phenylpiracetam, phenylpiracetam hydrazide, piracetam, p It is further assumed that compositions with racetums such as lamiracetam, rolipram, roldiracetam and / or celetracetam may also be used to prepare synergistic mixtures and compositions, particularly when the ratio of the compound of formula (I) or formula (II) to the enantiomer of the racetum or other racetum is selected within the range disclosed herein for mixtures of the compound of formula (I) and the compound of formula (II). It is further assumed that compositions of a compound of formula (I) or a compound of formula (II) with other compounds, such as dimiracetam or dimiracetam-like compounds disclosed in U.S. Patent No. 7,544,705 or U.S. Patent No. 8,334,286, may also be used to prepare synergistic mixtures and compositions, particularly when the ratio of the compound of formula (II) (or (I)) to the dimiracetam-like compound or the enantiomer of the dimiracetam-like compound is selected within the range disclosed herein for mixtures of the compound of formula (I) and the compound of formula (II).

[0056] The present invention also relates to a method for treating and / or preventing a disease, injury, or disorder, comprising the step of administering to a subject the composition described in claim 1, wherein the disease, injury, or disorder is peripheral sensory neuropathy, seizures, depression, or cognitive impairment. In this method, the disease, injury, or disorder is preferably peripheral sensory neuropathy, neuropsychiatric disorder, motor neuron disorder, or motor disorder. More preferably, the disease, injury, or disorder is peripheral sensory neuropathy. The peripheral sensory neuropathy is preferably peripheral neuropathic pain. Peripheral sensory neuropathy is preferably selected from diabetic neuropathy, postherpetic neuropathy, low back pain, sacral pain, surgical pain, crush injury, spinal injury, complex regional pain syndrome, phantom limb sensation, peripheral sensory neuropathy associated with osteoarthritis, peripheral sensory neuropathy associated with rheumatoid arthritis, peripheral sensory neuropathy associated with autoimmune osteoarthritis, headache, fibromyalgia, peripheral sensory neuropathy induced by bacterial growth inhibitory therapy, peripheral sensory neuropathy induced by chemotherapeutic agents, peripheral sensory neuropathy associated with visceral injury, peripheral sensory neuropathy associated with osteonecrosis, peripheral sensory neuropathy associated with human immunodeficiency virus infection, peripheral neuropathic pain, or peripheral sensory neuropathy induced by antiviral agents. In some cases, peripheral sensory neuropathy is peripheral sensory neuropathy induced by chemotherapeutic agents or peripheral sensory neuropathy induced by antiviral agents. In some cases, peripheral sensory neuropathy is peripheral sensory neuropathy induced by chemotherapeutic agents, which are selected from the group consisting of kinase inhibitors, proteasome inhibitors, taxanes, vinca alkaloids, and platinum salts, and are preferably selected from sorafenib, sunitinib, afatinib, axitinib, vandetanib, vemurafenib, ixazomib, bortezomib, paclitaxel, docetaxel, cabazitaxel, vincristine, vinblastine, vindesine, vinorelbine, nedaplatin, lovaplatin, picoplatin, satraplain, cisplatin, carboplatin, and oxaliplatin. In some cases, peripheral sensory neuropathy is peripheral sensory neuropathy induced by antiviral agents, which are nucleoside reverse transcriptase inhibitors.In some cases, nucleoside reverse transcriptase inhibitors include zalcitabine, didanosine, stavudine, or zidovudine.

[0057] In some cases, the method further includes a step of administering an antitumor drug, which is selected from the group consisting of kinase inhibitors, proteasome inhibitors, taxanes, vinca alkaloids, and platinum salts. In some cases, the antitumor drug is selected from the group consisting of sorafenib, sunitinib, afatinib, axitinib, vandetanib, vemurafenib, ixazomib, bortezomib, paclitaxel, docetaxel, cabazitaxel, vincristine, vinblastine, vindesine, vinorelbine, nedaplatin, lovaplatin, picoplatin, satraplain, cisplatin, carboplatin, and oxaliplatin. In some cases, the method further includes a step of administering an antiviral drug, which is a nucleoside or nucleotide. In some cases, the antiviral drug is zalcitabine, didanosine, stabudine, or zidovudine. In some cases, the composition is administered orally twice daily in doses ranging from 10 mg to 3000 mg per dose, from 20 mg to 2000 mg per dose, or from 50 mg to 1000 mg per dose.

[0058] The present invention further relates to a method for enhancing learning and memory, comprising the step of administering a composition of the present invention as described herein to a subject. In some cases of this method, the subject is a healthy subject. Non-patent references cited herein are abbreviated with the first author and publication year. The complete list of cited references is provided below. TIFF2022510362000006.tif246169 TIFF2022510362000007.tif233170 TIFF2022510362000008.tif229170 TIFF2022510362000009.tif129170 [Examples]

[0059] The examples of the present invention are illustrative and not limiting. Samples of racemic 2-phenylsulfonyl-hexahydro-pyrrolo[1,2-a]pyrazine-6(2H)-one and its derivatives, as well as the individual enantiomers of formulas (I) and (II), can be synthesized using commercially available starting materials, such as those purchased from Sigma-Aldrich. These commercially available supplies can be used as received from the supplier without further purification using preparation and synthesis methods and techniques well known to those skilled in the art.

[0060] (Example 1) Synthesis of 2-phenylsulfonyl-hexahydro-pyrrolo[1,2-a]pyrazine-6(2H)-one A racemic mixture of the (R)-enantiomer, the (S)-enantiomer, and 2-phenylsulfonyl-hexahydro-pyrrolo[1,2-a]pyrazine-6(2H)-one was prepared according to the methods described in Manetti D, et al. 2000; Martini E, et al. 2005; and Scapecchi S, et al. 2004. The enantiomer excess of the synthesized (R)- and (S)- derivatives was determined as described in Manetti D, et al. 2000. The enantiomer excess of the (R)- and (S)-enantiomers is 96% or more for each enantiomer when used separately to prepare the compositions of the present invention.

[0061] To achieve desired enantiomer excess rates of 20% or more ee (excess (R)) and 50% or less ee (excess (R)), as well as other desired specific compositions according to the present invention, several methods known to those skilled in the art can be applied. For example, the compositions can be prepared by mixing the individual enantiomers, or by mixing a racemic mixture of 2-phenylsulfonyl-hexahydro-pyrrolo[1,2-a]pyrazine-6(2H)-one with respective amounts of the (R)-enantiomer. Furthermore, starting from the racemic 2-phenylsulfonyl-hexahydro-pyrrolo[1,2-a]pyrazine-6(2H)-one, a portion or all of the (S)-enantiomer can be removed by preparative chiral column chromatography.

[0062] (Example 2) A rat model of induced peripheral neuropathy pain. Evaluation of pain response The effects of single doses of the test compound, vehicle, and control were evaluated at the peak pain response in the models under assessment. Subsequently, repeated doses of 2-phenylsulfonyl-hexahydro-pyrrolo[1,2-a]pyrazine-6(2H)-one or a mixture of derivatives were studied to assess the potential development of tolerance. Both hyperalgesia and allodynia were evaluated. All efficacy evaluations were performed by physicians who were unaware of the rat treatment allocation.

[0063] The results are expressed as the minimum dose at which a statistically significant difference is observed (via the same route) when compared to injured rats whose vehicle administration time was matched via the directed route. Analysis of variance (ANOVA), followed by Fisher's constrained minimum significance procedure for post-hoc comparisons, was used to examine the significance of two means of hyperalgesic behavioral outcomes: the Randall & Selitto device paw pressure test ("anti-hyperalgesia"), the Von Frey test ("mechanical allodynia"), or the cold plate test ("cold allodynia"). A P value ≤ 0.05 was considered significant. This definition applies to any dose designated herein as "statistically significant" inhibiting.

[0064] Paw pressure test (hyperalgesia) The mechanical sensitivity of the paw was determined using the Randall & Selitto apparatus (Randall and Selitto, 1957), which applies a force increasing at a constant rate (32 g / sec). The stimulus that elicited paw escape was evaluated at different times before and after treatment. The results represent the mean mechanical threshold for paw escape and are expressed in grams. To avoid possible injury to the rat's paw, the maximum force applied was set to 240 g. In the single-dose protocol, a paw pressure test was performed before treatment (before administration) and at regular intervals after treatment. Von Frey test (mechanical allodynia) Each animal was placed in a chamber with a mesh metal floor, covered by a plastic dome. Inside the dome, the animals could walk freely but could not jump. Mechanical stimulation was then applied to the central plantar skin of the left hind foot using an electronic von Frey device (37400 Dynamic Plantar Aesthesiometer, Ugo Basile, Comerio, Varese, Italy). The cutoff was set to 50 g, and the rate of force increase (ramp time) was set to 20 seconds. In the single-dose protocol, pain threshold measurements were taken before treatment (before administration) and at regular intervals after treatment. In the repeated-treatment protocol, pre-test values ​​were measured 13 hours after the last administration. The animals were then given a new dose and the treatment was performed at the indicated time. Results are expressed in grams and represent the mean ± SEM of the mechanical threshold. Cold plate test (cold allodynia) The animals were placed in a stainless steel box (12cm x 20cm x 10cm) equipped with a cold plate as the floor. The temperature of the cold plate was maintained at a constant 4°C ± 1°C. Pain-related behaviors (i.e., lifting and licking of the hind legs) were observed, and the time of the first sign was recorded. A cutoff time of 60 seconds was set for the latency of leg lifting or licking (Di Cesare Mannelli et al. Exp Neurol 261:22-33, 2014).

[0065] (Example 2A) Effects of compounds in chronic strangulation injury models To evaluate the effects of the test compound on mechanoalgesia compared to a vehicle or selected control, we selected the rat chronic constriction injury model (Wang and Wang, 2003), a widely accepted model of painful neuropathy. Neuropathy was induced following the procedure described by Bennett and Xie (1998). Briefly, rats were anesthetized under sterile conditions by intraperitoneal administration of 400 mg / kg of chloral hydrate, and the right common sciatic nerve was exposed at the mid-femoral level by blunt dissection. Proximal to the trifida, the surrounding connective tissue was carefully removed from the nerve, and four chromic-cut-good ligatures (4-0, Ethicon, Norderstedt, Germany) were loosely tied around it at approximately 1 mm intervals. After confirming hemostasis, the incision was closed into layers. The animals were then allowed to recover from anesthesia and surgery, maintained one per cage, and given water and standard feed ad libitum. This procedure induces the appearance of hyperalgesia and allodynia in response to mechanical stimulation. This becomes apparent 2–5 days after injury, reaching their maximum severity at approximately 14 days.

[0066] [Table 1]

[0067] (Example 2B) Effects of compounds in a MIA-induced osteoarthritis model Model of osteoarthritis of the knee A single intra-articular injection of sodium monoiodoacetate (MIA) was administered to the knee joint of rats according to the method described by Fernihough J et al., 2004. Sodium monoiodoacetate (MIA) inhibits chondrocyte metabolism, leading to chondrolysis in the form of osteoarthritis-like focal lesions in the cartilage associated with subchondral bone thickening 14 days after administration (Guingamp et al., 1997). Therefore, this model can easily and rapidly reproduce in rats osteoarthritis-like lesions and dysfunction similar to those observed in human disease (Guzman et al., 2003). Seven days after injection, the inflammatory component subsided, and any remaining pain was considered virtually neuropathic pain. Briefly, rats were deeply anesthetized with diethyl ether. Following the abolition of the hind paw pinch-escape reflex, a 27-gauge needle was introduced into the joint cavity between the tibial plateau and the femoral condyle. Once properly positioned, 2 mg of MIA was diluted in 25 mL of 1% CMC (carboxymethylcellulose in water, Sigma-Aldrich, Italy) and injected into one knee joint, allowing the rats to recover for 14 days before pain assessment.

[0068] [Table 2]

[0069] (Example 2C) Diabetic peripheral neuropathy 200 mg / kg of streptozotocin (Wako Pure Chemicals, Richmond, VA), prepared in saline solution adjusted to pH 4.5 with 0.1N citrate buffer, was intravenously injected into the tail of mice (approximately 30 g). The vehicle was injected alone into age-matched non-diabetic control mice. The streptozotocin solution was freshly prepared due to the limited stability of the compound. Animals were maintained in groups of four per cage and provided with special care including supplemental feed and water. Cage flooring was changed daily. In a series of preliminary control experiments, serum glucose levels were spectroscopically measured on days 7, 14, and 21 after streptozotocin treatment and were found to be consistent with glucosuria levels (above 300 mg / dl) throughout the period. Serum glucose levels were measured by glucose oxidase from blood samples obtained by tail vein puncture. It was found that animals developed both thermal and mechanical hyperalgesia at 1, 2, and 3 weeks after streptozotocin treatment. Animals 7 days after streptozotocin treatment were used in the study.

[0070] ICV injection was performed into the left ventricular ventricle of mice. The injection was carried out using a Hamilton microliter syringe fitted with a 26-gauge needle, following the method of Haley and McCormick (1957). The injection site was 2 mm caudal and 2 mm lateral to the bregma, and 3 mm deep from the skull surface. The injection volume was 5 μl. [Table 3]

[0071] (Example 3A) Chemotherapy-induced peripheral sensory neuropathy - oxaliplatin model In adult rats, peripheral sensory neuropathy was induced by intraperitoneal administration of oxaliplatin (Tocris) in saline at a dose of 2.4 mg / kg once daily for 5 consecutive weeks for 3 weeks (accumulative dose of 36 mg / kg), according to Cavaletti et al., 2001. The effect of repeated oral administration of a preferred composition of the present invention having a 50% enantiomer excess of (R)-uniphyllum corresponding to a racemic (R):(S) ratio of 3:1 for oxaliplatin-induced mechanoalgesia was evaluated, starting 21 days after the first oxaliplatin administration.

[0072] [Table 4]

[0073] (Example 3B) Chemotherapy-induced peripheral sensory neuropathy - vincristine model [Table 5]

[0074] (Example 3C) Chemotherapy-induced peripheral sensory neuropathy - Paclitaxel model [Table 6]

[0075] The efficacy of 2-(2-fluorobenzenesulfonyl)hexahydropyrrolo[1,2-a]pyrazine-6-one derivatives (R-enantiomer=NT-24336, S-enantiomer=NT-24781, R:S mixtures 1:1, 1:3, and 3:1) was compared after a single acute administration (1 mg / kg, intravenous) in mechanically induced models of hyperalgesia and allodynia in male adult Sprague Dawley rats.

[0076] Evaluation of mechanical allodynia (von Frey test) revealed that a non-racemic mixture containing 3 parts R-enantiomer and 1 part S-enantiomer was by far the most active and statistically significantly more effective than the R-enantiomer alone (P<0.05 at 15 minutes post-administration and P<0.01 at 30 minutes post-administration). The 1:1 racemic mixture was slightly effective, and the S-enantiomer and the 1:3 mixture of R- and S-enantiomers were almost inactive (see Figure 1). Mechanosalgesia (Randall & Selitto, paw pressure test) assays showed the same ranking of efficacy (see Figure 2).

[0077] Figure 1 shows the effects of the R- and S-enantiomers of 2-(2-fluorobenzenesulfonyl)hexahydropyrrolo[1,2-a]pyrazine-6-one, as well as mixtures of their different enantiomers, on paclitaxel-induced mechanical allodynia. Paclitaxel (2 mg / kg, intraperitoneal administration) was administered on days 1, 3, 5, and 8. The test compound was dissolved in saline and administered intravenously at a dose of 1 mg / kg to adult male Sprague-Dawley rats (Charles River, Italy, 220-250 g mass). Data were obtained 0-75 minutes after injection and are expressed as mean ± sem of 6 animals. *P<0.05 and **<0.01 for vehicle + paclitaxel-treated rats; °P<0.05 and °°P<0.01 for NT24336(R)-treated group.

[0078] Figure 2 shows the effects of the R- and S-enantiomers of 2-(2-fluorobenzenesulfonyl)hexahydropyrrolo[1,2-a]pyrazine-6-one, as well as mixtures of their different enantiomers, on paclitaxel-induced mechanoalgesia. Paclitaxel (2 mg / kg, intraperitoneal administration) was administered on days 1, 3, 5, and 8. The test compound was dissolved in saline and administered intravenously at a dose of 1 mg / kg to adult male Sprague-Dawley rats (Charles River, Italy, 220-250 g mass). Data were obtained 0-75 minutes after injection and are expressed as mean ± sem of 6 animals. For vehicle + paclitaxel-treated rats, *P < 0.05 and ** < 0.01.

[0079] (Example 4) In vivo anti-amnesic activity in the passive avoidance paradigm of mice. Racemic mixtures, as well as R and S enantiomers, were tested in a passive avoidance test in mice at oral doses of 3, 10, and 30 mg / kg 30 minutes after administration. Methods. The experiment was conducted according to the step-through method described by Jarvik ME ad Kopp R, Psychol Rep, 21:221-224, 1967. The apparatus consisted of a two-compartment acrylic box, with the light compartment connected to the dark compartment by a guillotine door. Mice received a painful electric shock (0.3 mA, 1 second) immediately upon entering the dark compartment. The experiment was conducted for two consecutive days. Mice were placed on the light compartment side of the two-compartment box, and the latency time before entering the dark compartment was measured during the training session on day 1 and again 24 hours later during the retention session on day 2. Mice were punished for entering the dark room during the training session and recalled it in the following session unless their memory was impaired by an amnesic agent. Mice that did not enter the dark compartment after a 60-second latency during the training session were excluded from the remainder of the experiment. Approximately 20-30% of the mice were excluded from each group. All drugs investigated were administered orally 30 minutes before the training session. For memory confusion, mice were injected with the amnesic drug scopolamine (1.5 mg / kg intraperitoneally) immediately after the completion of the training session.

[0080] Vehicle-treated mice received an intraperitoneal injection of saline as a control for scopolamine injection immediately after the training session. The test was repeated 24 hours later (holding session). No drug was administered on day 2. The maximum acceptable entry latency during the holding session was 180 seconds. The results are shown in Table 7. [Table 7]

[0081] The claimed ratio R:S enantiomer of 2-phenylsulfonyl-hexahydro-pyrrolo[1,2-a]pyrazine-6(2H)-one leads to significantly better inhibition of glutamate release from rat spinal cord synaptosomes, more potent treatment of peripheral neuropathic pain, stronger anti-amnesic and antidepressant effects compared to when the racemic mixture of 2-phenylsulfonyl-hexahydro-pyrrolo[1,2-a]pyrazine-6(2H)-one is used.

[0082] All patents, publications, and abstracts cited herein are incorporated herein by reference in their entirety. Various embodiments of the present invention are described as realizations of various objectives of the present invention. It should be recognized that these embodiments are merely illustrative of the principles of the present invention. Numerous modifications and alterations will be readily apparent to those skilled in the art without departing from the spirit and scope of the present invention as defined in the following claims.

Claims

1. Compounds of formula (I) and compounds of formula (II) 【Chemistry 1】 (Wherein Z is A linear, branched or cyclic C optionally substituted with one or more F 1-4 - an alkyl group, or R 1 and R 2 Phenyl group substituted with and R 1 is selected from the group consisting of hydrogen, fluoro, chloro, cyano, trifluoromethyl, and methyl; R 2 is independently selected from the group consisting of hydrogen, fluoro, chloro, and methyl; R 1 and R 2 independently occupy any two positions on the phenyl ring), and / or a pharmaceutically acceptable solvate or co-crystal thereof, A composition, wherein the enantiomeric excess (ee) of the compound of formula (I) is 20% or more and 50% or less.

2. The compound of formula (I) is a compound of formula (Ia), and / or a pharmaceutically acceptable solvate or co-crystal thereof, and the compound of formula (II) is a compound of formula (IIa), and / or a pharmaceutically acceptable solvate or co-crystal thereof, 【Chemistry 2】 (In the formula, R 1 is selected from the group consisting of hydrogen, fluoro, chloro, cyano, trifluoromethyl, and methyl; R 2 is independently selected from the group consisting of hydrogen, fluoro, chloro, and methyl; R 1 and R 2 independently occupy any two positions on the phenyl ring), 2. The composition of claim 1, wherein the enantiomeric excess (ee) of the compound of formula (Ia) is 20% or more and 50% or less.

3. 3. The composition according to claim 1 or 2, wherein the enantiomeric excess (ee) of the compound of formula (Ia) is 30% or more and 50% or less, preferably 35% or more and 50% or less.

4. 4. The composition of any one of claims 1 to 3, wherein the compound of formula (I) and / or its pharmaceutically acceptable solvate or co-crystal and the compound of formula (II) and / or its pharmaceutically acceptable solvate or co-crystal are packaged separately.

5. 2. The composition of claim 1, wherein the composition is a non-racemic mixture of 2-([2-fluorophenyl]sulfonyl)-hexahydropyrrolo[1,2-a]pyrazin-6(2H)-one and a pharmaceutically acceptable solvate or co-crystal thereof, wherein the non-racemic mixture comprises the compound of formula (I) and the compound of formula (II) in an enantiomeric excess (ee) of the compound of formula (I) of greater than or equal to 20% and less than or equal to 50%.

6. 2. The composition of claim 1, wherein the composition is a non-racemic mixture of 2-([4-fluorophenyl]sulfonyl)-hexahydropyrrolo[1,2-a]pyrazin-6(2H)-one and a pharmaceutically acceptable solvate or co-crystal thereof, wherein the non-racemic mixture comprises the compound of formula (I) and the compound of formula (II) in an enantiomeric excess (ee) of the compound of formula (I) of greater than or equal to 20% and less than or equal to 50%.

7. 2. The composition of claim 1, wherein the composition is a non-racemic mixture of 2-([3-fluorophenyl]sulfonyl)-hexahydropyrrolo[1,2-a]pyrazin-6(2H)-one and a pharmaceutically acceptable solvate or co-crystal thereof, wherein the non-racemic mixture comprises the compound of formula (I) and the compound of formula (II) in an enantiomeric excess (ee) of the compound of formula (I) of greater than or equal to 20% and less than or equal to 50%.

8. A pharmaceutical composition comprising the composition of any one of claims 1 to 7 and a pharmaceutically acceptable carrier.

9. A kit of parts comprising a compound of formula (I) and a compound of formula (II), and instructions for combining the compound of formula (I) and the compound of formula (II) to obtain an enantiomeric excess (ee) of the compound of formula (I) of greater than or equal to 20% and less than or equal to 50%.

10. A composition according to any one of claims 1 to 7 or a pharmaceutical composition according to claim 8 or a kit of parts according to claim 9 for use as a medicament.

11. 11. The composition or pharmaceutical composition or kit according to claim 10, for use in the treatment and / or prevention of a disease or disorder, wherein the disease, injury or disorder is selected from peripheral sensory neuropathy, stroke, depression or cognitive impairment.

12. 11. The composition or pharmaceutical composition or kit of claim 10, for use in the treatment and / or prevention of a disease, injury or disorder, wherein the disease, injury or disorder is selected from a peripheral sensory neuropathy, a neuropsychiatric disorder, a motor neuron disorder, or a movement disorder.

13. 13. The composition or pharmaceutical composition or kit for use according to claim 11 or 12, wherein the disease, injury or disorder is peripheral sensory neuropathy, preferably the peripheral sensory neuropathy is peripheral neuropathic pain.

14. 13. The composition or pharmaceutical composition or kit for use according to claim 11 or 12, wherein the disease, injury or disorder is depression or anhedonia, preferably wherein the depression or anhedonia has not responded to prior treatment with an established antidepressant.

15. 14. The composition or pharmaceutical composition or kit for use according to claim 11 or 13, wherein the peripheral sensory neuropathy is diabetic neuropathy, postherpetic neuropathy, low back pain, sacral pain, surgical pain, crush injury, spinal injury, complex regional pain syndrome, phantom limb sensation, peripheral sensory neuropathy associated with osteoarthritis, peripheral sensory neuropathy associated with rheumatoid arthritis, peripheral sensory neuropathy associated with autoimmune osteoarthritis, headache, fibromyalgia, peripheral sensory neuropathy induced by antiblastic therapy, peripheral sensory neuropathy induced by chemotherapeutic agents, peripheral sensory neuropathy associated with visceral injury, peripheral sensory neuropathy associated with osteonecrosis, peripheral sensory neuropathy associated with human immunodeficiency virus infection, peripheral neuropathic pain, or peripheral sensory neuropathy induced by an antiviral agent.

16. 15. The composition or pharmaceutical composition or kit for use according to any one of claims 11 to 14, wherein the peripheral sensory neuropathy is selected from chemotherapeutic agent-induced peripheral sensory neuropathy or antiviral agent-induced peripheral sensory neuropathy.

17. 16. The composition or pharmaceutical composition or kit for use according to any one of claims 11 to 15, wherein the peripheral sensory neuropathy is peripheral sensory neuropathy induced by a chemotherapeutic agent, and the chemotherapeutic agent is selected from the group consisting of kinase inhibitors, proteasome inhibitors, taxanes, vinca alkaloids, and platinum salts, and is preferably selected from sorafenib, sunitinib, afatinib, axitinib, vandetanib, vemurafenib, ixazomib, bortezomib, paclitaxel, docetaxel, cabazitaxel, vincristine, vinblastine, vindesine, vinorelbine, nedaplatin, lobaplatin, picoplatin, satraplatin, cisplatin, carboplatin, and oxaliplatin.

18. 18. The composition or pharmaceutical composition or kit for use according to any one of claims 11 to 17, wherein the peripheral sensory neuropathy is peripheral sensory neuropathy induced by an antiviral agent, and the antiviral agent is a nucleoside reverse transcriptase inhibitor, preferably selected from zalcitabine, didanosine, stavudine and zidovudine.

19. 19. The composition or pharmaceutical composition or kit for use according to any one of claims 11 to 18, wherein the composition or pharmaceutical composition is used together with at least one anti-tumor drug, preferably selected from the group consisting of kinase inhibitors, proteasome inhibitors, taxanes, vinca alkaloids and platinum salts, more preferably selected from sorafenib, sunitinib, afatinib, axitinib, vandetanib, vemurafenib, ixazomib, bortezomib, paclitaxel, docetaxel, cabazitaxel, vincristine, vinblastine, vindesine, vinorelbine, nedaplatin, lobaplatin, picoplatin, satraplatin, cisplatin, carboplatin and oxaliplatin.

20. 20. A composition or pharmaceutical composition or kit for use according to any one of claims 11 to 19, wherein the composition or pharmaceutical composition is used together with at least one antiviral drug, the antiviral drug being preferably selected from nucleosides or nucleotides, more preferably zalcitabine, didanosine, stavudine and zidovudine.

21. 21. The composition or pharmaceutical composition or kit for use according to any one of claims 11 to 20, wherein the composition or pharmaceutical composition is to be administered orally twice daily at a dose of between 10 mg and 3000 mg per dose, more preferably between 20 mg and 2000 mg per dose, even more preferably between 50 mg and 1000 mg per dose.

22. 10. A composition according to any one of claims 1 to 7 or a pharmaceutical composition according to claim 8 or a kit of parts according to claim 9 for use in a method for enhancing learning and memory.

23. a compound of formula (I) and a compound of formula (II), or Compound of formula (I) and racemic mixture of compounds of formulas (I) and (II) 9. A method for preparing a composition according to any one of claims 1 to 7 or a pharmaceutical composition according to claim 8, comprising combining:

24. Use of a compound of formula (I) and / or a compound of formula (II) and / or a racemate of compounds of formula (I) and (II) in the preparation of a composition according to any one of claims 1 to 7 or a pharmaceutical composition according to claim 8 or a kit according to claim 9.

25. 10. Non-therapeutic use of a composition according to any one of claims 1 to 7 for enhancing learning and memory in a healthy subject.